Methylprednisolone
Based on 21 publication(s) in Google Scholar
Methylprednisolone (U 7532) is a synthetic corticosteroid with anti-inflammatory and immunomodulating properties. Methylprednisolone improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.78%
- CAS No.: 83-43-2
- Formule: C22H30O5
- Masse moléculaire:374.47
-
Stockage:
4°C, protect from light
* In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-17463
PrednisoloneGlucocorticoid -
HY-N0583
HydrocortisoneGlucocorticoid Receptor Agonist -
HY-13580
BudesonideGlucocorticoid Receptor Agonist -
HY-14648
DexamethasoneGR Agonist -
HY-B0579
Cyclosporin ACalcineurin Inhibitor -
HY-13756
TacrolimusCalcineurin Inhibitor -
HY-B0199
Mycophenolate MofetilIMPDH Inhibitor -
HY-B0214
PrednisoneGlucocorticoid Receptor Agonist -
HY-Y0873
PEG300Neutral Polymer -
HY-Y0320
Dimethyl sulfoxide, meets analytical specification of Ch.P.Aprotic Solvent -
HY-Y1891
Tween 80 -
HY-10219
RapamycinmTOR Inhibitor
Publications Citing Use of MedChemExpress (MCE) Methylprednisolone
More- Bone Res. 2025 Jan 26;13(1):18. [Abstract]
- Nucleic Acids Res. 2021 Jan 8;49(D1):D1113-D1121. [Abstract]
- Chem Eng J. 2026 Mar 3.
- Int J Biol Sci. 2020 Jun 27;16(13):2382-2391. [Abstract]
- Mol Med. 2024 Jul 31;30(1):111. [Abstract]
- Blood Adv. 2026 Feb 5:bloodadvances.2025017189. [Abstract]
- Redox Rep. 2025 Dec;30(1):2585221. [Abstract]
- Biochem Pharmacol. 2025 Jun:236:116870. [Abstract]
- Drug Des Devel Ther. 2022 Nov 15:16:3929-3946. [Abstract]
- Commun Biol. 2025 Dec 2;9(1):27. [Abstract]
- Commun Biol. 2025 Nov 25;8(1):1682. [Abstract]
- Mol Med Rep. 2026 Jan;33(1):49. [Abstract]
- Sci Rep. 2026 May 7;16(1):21071. [Abstract]
- Sci Rep. 2025 Dec 15;16(1):986. [Abstract]
- Biomedicines. 2026 Feb 9;14(2):400. [Abstract]
- iScience. 2023 Apr 5,23.
- Exp Cell Res. 2020 Aug 1;393(1):112054. [Abstract]
- BMC Pulm Med. 2022 Sep 16;22(1):348. [Abstract]
- Toxicol Mech Methods. 2026 Jun 19:1-15. [Abstract]
- PLoS One. 2025 Jun 20;20(6):e0325190. [Abstract]
- Drug Test Anal. 2021 Feb;13(2):283-298. [Abstract]
Customer Validation & Images
-
Histological Imaging/Staining
-
RT-PCR
-
In Vivo Efficacy Study
-
WB
-
WB
Activité biologique
Description
IC50 & Target
Glucocorticoid Receptor
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HepG2 | EC50 |
12.6 μM
Compound: 6-alpha-Methylprednisolone
|
Activation of human PXR expressed in human HepG2 (DPX-2) cells assessed as induction of CYP3A4 after 24 hrs by luminescent analysis
Activation of human PXR expressed in human HepG2 (DPX-2) cells assessed as induction of CYP3A4 after 24 hrs by luminescent analysis
|
[PMID: 20966043] |
| HepG2 | EC50 |
4 μM
Compound: 6-alpha-Methylprednisolone
|
Activation of rat PXR expressed in human HepG2 cells after 24 hrs by luciferase reporter gene based luminescent analysis
Activation of rat PXR expressed in human HepG2 cells after 24 hrs by luciferase reporter gene based luminescent analysis
|
[PMID: 20966043] |
In Vitro
Methylprednisolone is commonly used for anti-inflammatory purposes. Methylprednisolone can be used in the study of bronchial inflammation or acute bronchitis caused by arthritis and various respiratory diseases[1]. Methylprednisolone can improve neurological recovery in acute spinal cord injury[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Induced Disease Models
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.
Methylprednisolone can be used in animal modeling to construct a femoral head necrosis model.
Administration: 30 mg/kg • im • Injection on the second, third and fourth day
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 83-43-2
-
Appearance Solid
-
Masse moléculaire 374.47
-
Formule C22H30O5
-
Color White to off-white
-
SMILES
O=C1C=C[C@]2(C)[C@@]3([H])[C@@H](O)C[C@]4(C)[C@@](O)(C(CO)=O)CC[C@@]4([H])[C@]3([H])C[C@H](C)C2=C1
-
Synonyms
U 7532
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, protect from light
* In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)
Publications (21)
-
Journal Impact Factor
-
Most Recent
-
Bone Res
Isovitexin targets SIRT3 to prevent steroid-induced osteonecrosis of the femoral head by modulating mitophagy-mediated ferroptosis. [Abstract]2025 Jan 26;13(1):18. PMID: 39865068 -
Nucleic Acids Res
COVID19 Drug Repository: text-mining the literature in search of putative COVID19 therapeutics. [Abstract]2021 Jan 8;49(D1):D1113-D1121. PMID: 33166390 -
-
Int J Biol Sci
Glucocorticoids improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels. [Abstract]2020 Jun 27;16(13):2382-2391. PMID: 32760206
Methylprednisolone purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2020 Jun 27;16(13):2382-2391. [Abstract]
After treatment of GES-1 cells with 100 nM glucocorticoids or chemicals for 48 h, the protein expression levels of ACE2 is examined. Compared to the blank control, Methylprednisolone reveals an activating effect on ACE2 expression.
-
Mol Med
Inhibition of insulin degrading enzyme suppresses osteoclast hyperactivity via enhancing Nrf2-dependent antioxidant response in glucocorticoid-induced osteonecrosis of the femoral head. [Abstract]2024 Jul 31;30(1):111. PMID: 39085816 -
Blood Adv
2026 Feb 5:bloodadvances.2025017189. PMID: 41643175 -
Redox Rep
Monoammonium glycyrrhizinate ameliorates mitochondrial dysfunction-mediated oxidative stress and neuroinflammation via the NRF2/NQO1 axis after spinal cord injury. [Abstract]2025 Dec;30(1):2585221. PMID: 41240391
Methylprednisolone purchased from MedChemExpress. Usage Cited in: Redox Rep. 2025 Dec;30(1):2585221. [Abstract]
Methylprednisolone (30 mg/kg; ip).Histopathological staining (HE) of spinal cord tissues at 28 dpi.
-
Biochem Pharmacol
Irisin alleviates steroid-induced vascular dysfunction by regulating the αVβ5-c-Abl-Caveolin-1 signaling pathway. [Abstract]2025 Jun:236:116870. PMID: 40086515 -
Drug Des Devel Ther
ED-71 Prevents Glucocorticoid-Induced Osteoporosis by Regulating Osteoblast Differentiation via Notch and Wnt/β-Catenin Pathways. [Abstract]2022 Nov 15:16:3929-3946. PMID: 36411860 -
Commun Biol
Pentraxin 3 ameliorates glucocorticoid-induced osteonecrosis of the femoral head via TLR4/NF-κB/FGF21 signaling axis. [Abstract]2025 Dec 2;9(1):27. PMID: 41331332
Methylprednisolone purchased from MedChemExpress. Usage Cited in: Commun Biol. 2025 Dec 2;9(1):27. [Abstract]
Flowchart of ONFH model on Ptx3-KO and wild-type mice.
-
Commun Biol
GDF11 alleviates glucocorticoid-induced osteonecrosis of the femoral head by regulating angiogenesis via the PI3K-AKT-eNOS pathway. [Abstract]2025 Nov 25;8(1):1682. PMID: 41291036
Methylprednisolone purchased from MedChemExpress. Usage Cited in: Commun Biol. 2025 Nov 25;8(1):1682. [Abstract]
The expression of GDF11, CD31 and VEGFA in the control group (untreated), Methylprednisolone (MP: 100 μM; 24 h) treatment group and MP+GDF11 treatment group (n=3 in each group) was detected by real-time quantitative PCR.
Methylprednisolone purchased from MedChemExpress. Usage Cited in: Commun Biol. 2025 Nov 25;8(1):1682. [Abstract]
Western blotting was performed to detect expression of PI3K, AKT, eNOS, p-PI3K, p-AKT, and p-eNOS in the following groups: Methylprednisolone (MP: 100 μM; 24 h), MP + GDF11-treated, MP + GDF11 + LY294002-treated, and MP + GDF11 + L-NAME-treated cells.
-
Mol Med Rep
NEDD4 regulates VEGF signaling and mTOR to promote angiogenesis and the cell cycle in steroid‑induced osteonecrosis of the femoral head. [Abstract]2026 Jan;33(1):49. PMID: 41268613 -
Sci Rep
Oleuropein attenuates steroid-induced osteonecrosis of the femoral head by inhibiting osteoblast apoptosis via activation of the PI3K-AKT-Bcl2 pathway. [Abstract]2026 May 7;16(1):21071. PMID: 42098216 -
Sci Rep
New insights into the mechanism of microvascular rarefaction via endothelial-mesenchymal transition in steroid-induced osteonecrosis of femoral head. [Abstract]2025 Dec 15;16(1):986. PMID: 41398023 -
Biomedicines
Kaempferol Alleviates Glucocorticoid-Induced Osteonecrosis of the Femoral Head by Modulating Macrophage M1/M2 Polarization Through RhoA/ROCK-Mediated Mitophagy Activation. [Abstract]2026 Feb 9;14(2):400. PMID: 41751299 -
-
Exp Cell Res
Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia. [Abstract]2020 Aug 1;393(1):112054. PMID: 32376287 -
BMC Pulm Med
Effects of different doses of methylprednisolone therapy on acute respiratory distress syndrome: results from animal and clinical studies. [Abstract]2022 Sep 16;22(1):348. PMID: 36114531 -
Toxicol Mech Methods
Glycycoumarin ameliorates pyroptosis in autoimmune hepatitis by activating autophagy and reducing NLRP3 inflammasome activation. [Abstract]2026 Jun 19:1-15. PMID: 42318851 -
PLoS One
PPARγ inhibitors enhance the efficacy of statin therapy for steroid-induced osteonecrosis of the femoral head by directly inhibiting apoptosis and indirectly modulating lipoprotein subfractions. [Abstract]2025 Jun 20;20(6):e0325190. PMID: 40540523 -
Drug Test Anal
High-throughput liquid chromatography tandem mass spectrometry assay as initial testing procedure for analysis of total urinary fraction. [Abstract]2021 Feb;13(2):283-298. PMID: 32852861
Solvant et solubilité
In Vitro:
DMSO : ≥ 100 mg/mL (267.04 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (protect from light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (protect from light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (5.55 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (5.55 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 25 mg/mL (66.76 mM); Suspended solution; Need ultrasonic and warming and heat to 60°C
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocole
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Pureté et documentation
-
Fiche technique (284 KB)
-
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Strupp, M., et al., Methylprednisolone, valacyclovir, or the combination for vestibular neuritis. N Engl J Med, 2004. 351(4): p. 354-61. [Content Brief]
[2]. Bracken, M.B., et al., A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med, 1990. 322(20): p. 1405-11. [Content Brief]
[4]. Fan Y,et al. Isovitexin targets SIRT3 to prevent steroid-induced osteonecrosis of the femoral head by modulating mitophagy-mediated ferroptosis. Bone Res. 2025 Jan 26;13(1):18. [Content Brief]
[5]. Yu R, et al. Physiologically Based Pharmacokinetic Modeling: The Reversible Metabolism and Tissue-Specific Partitioning of Methylprednisolone and Methylprednisone in Rats. Drug Metab Dispos. 2024 Jun 17;52(7):662-672. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (protect from light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6704 mL | 13.3522 mL | 26.7044 mL | 66.7610 mL |
| 5 mM | 0.5341 mL | 2.6704 mL | 5.3409 mL | 13.3522 mL | |
| 10 mM | 0.2670 mL | 1.3352 mL | 2.6704 mL | 6.6761 mL | |
| 15 mM | 0.1780 mL | 0.8901 mL | 1.7803 mL | 4.4507 mL | |
| 20 mM | 0.1335 mL | 0.6676 mL | 1.3352 mL | 3.3381 mL | |
| 25 mM | 0.1068 mL | 0.5341 mL | 1.0682 mL | 2.6704 mL | |
| 30 mM | 0.0890 mL | 0.4451 mL | 0.8901 mL | 2.2254 mL | |
| 40 mM | 0.0668 mL | 0.3338 mL | 0.6676 mL | 1.6690 mL | |
| 50 mM | 0.0534 mL | 0.2670 mL | 0.5341 mL | 1.3352 mL | |
| 60 mM | 0.0445 mL | 0.2225 mL | 0.4451 mL | 1.1127 mL | |
| 80 mM | 0.0334 mL | 0.1669 mL | 0.3338 mL | 0.8345 mL | |
| 100 mM | 0.0267 mL | 0.1335 mL | 0.2670 mL | 0.6676 mL |
Methylprednisolone Related Classifications
HY-B0260 Related Classifications
Powered by Bioz